Vaccine antigen with increased immunogenicity
US-2018265553-A1 · Sep 20, 2018 · US
Broadly protective Shigella vaccine based on type III secretion apparatus proteins
US9492523B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9492523-B2 |
| Application number | US-201213709689-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 10, 2012 |
| Priority date | Dec 9, 2011 |
| Publication date | Nov 15, 2016 |
| Grant date | Nov 15, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Broad-based, cross-protective, O-serotype independent vaccines against Shigella and related pathogenic organisms are provided. The vaccines comprise one or more of the type III secretion (TTS) apparatus needle proteins IpaD and IpaB, and/or the IpaB cognate chaperone protein IpgC. Chimeric proteins of IpaD and IpaB, and/or IpgC are also encompassed.
First claim
Opening claim text (preview).
What is claimed is: 1. A cross-protective, O-serotype independent vaccine against Shigella in a form suitable for administration to an animal, comprising at least one fusion protein comprising IpaB and IpaD, wherein said vaccine is free of Shigella lipopolysaccharide (LPS). 2. The cross-protective, O-serotype independent vaccine of claim 1 , wherein said vaccine comprises a complex of i) said fusion protein comprising IpaB and IpaD; and ii) IpgC. 3. The vaccine of claim 1 , wherein said fusion protein is or includes SEQ ID NO:4. 4. A fusion protein that is or includes SEQ ID NO:4. 5. A cross-protective, O-serotype independent vaccine against Shigella that is comprised of a fusion protein of IpaB and IpaD, wherein said vaccine is free of Shigella lipopolysaccharide (LPS). 6. The vaccine of claim 5 , wherein said fusion protein is or includes SEQ ID NO:4.
Assignees
Inventors
Classifications
raising an immune response against a target which is not the antigen used for immunisation · CPC title
- A61K39/0283Primary
Shigella · CPC title
intranasal · CPC title
Bacterial toxins · CPC title
characterised by the route of administration · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9492523B2 cover?
- Broad-based, cross-protective, O-serotype independent vaccines against Shigella and related pathogenic organisms are provided. The vaccines comprise one or more of the type III secretion (TTS) apparatus needle proteins IpaD and IpaB, and/or the IpaB cognate chaperone protein IpgC. Chimeric proteins of IpaD and IpaB, and/or IpgC are also encompassed.
- Who is the assignee on this patent?
- Univ Oklahoma State
- What technology area does this patent fall under?
- Primary CPC classification A61K39/0283. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).